FDA Drug Topics: An Overview of FDA’s Project Facilitate Oncology Expanded Access Program
December 12, 2023
FDA's Division of Drug Information in the Center for Drug Evaluation and Research (CDER) sponsors a series of educational webinars targeting the needs of health care professionals and students. The webinars cover a broad range of FDA drug regulation and medication safety topics. These focused webinars support FDA's mission of promoting and protecting public health through interaction and education to strengthen current and future partnerships and relationships with clinicians and researchers.
Expanded access, sometimes called "compassionate use", is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available. This webinar will review the oncology expanded access pathway and Project Facilitate's role in making oncology expanded access more accessible for healthcare and regulatory professionals.
- FDA Project Facilitate Website: https://www.fda.gov/about-fda/oncology-center-excellence/project-facilitate
- FDA Expanded Access Site: https://www.fda.gov/news-events/public-health-focus/expanded-access
- FDA Expanded Access Information for Physicians: https://www.fda.gov/news-events/expanded-access/expanded-access-information-physicians
- FDA Expanded Access to Investigational Drugs for Treatment Use (Questions and Answers): https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expanded-access-investigational-drugs-treatment-use-questions-and-answers-0
- Title 21 Code of Federal Regulations – Expanded Access: https://ecfr.io/Title-21/Part-312/Subpart-I
- Reagan-Udall Foundation EA navigator: https://navigator.reaganudall.org/expanded-access-navigator
- Explain how to utilize FDA's Drug Information, medication safety resources, and regulatory guidances to improve delivery of patient care and optimize outcomes.
- Describe and inform health care providers of recent labeling, policy and regulatory changes which would impact prescribing and medication management to optimize patient care.
- Define expanded access and the key requirements for an expanded access request for an individual patient.
- Summarize the key responsibilities of the oncology healthcare professional when considering expanded access for a patient.
- Identify resources available to healthcare professionals considering submission of an oncology expanded access request for an individual patient.
- Describe how Project Facilitate is a resource to navigate the oncology Expanded Access pathway.
This activity is intended for physicians, pharmacists, pharmacy technicians, nurses, Certified Public Health (CPH), and physician assistants.
Lecture 1 December 12, 2023
|1:00 - 2:00 PM EST||An Overview of FDA’s Project Facilitate Oncology Expanded Access Program||
Mitchell Chan, PharmD, BCPS
Cameron Wilson, PharmD
Physicians, physician assistants, pharmacists, nurses, pharmacist techs, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.
Attention Pharmacists and Pharmacy Techs: Failure to provide your correct NABP AND Date of Birth information, in the required format, may result in the loss of credit for this activity. NABP profile number should be the 6-7 digit profile number assigned by the CPE Monitor and your birth date should be in the MMDD format (e.g. 0721) Do not provide your pharmacy license number. Please click the "My Account" tab and then navigate to "Edit Contact Information" to verify that your information is correct.
Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit.Physicians, physician assistants, and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 8 weeks after the last session of the activity to obtain their CE credit.
- Chan, Mitchell, PharmD, BCPS, Clinical Analyst, FDA - nothing to disclose
- Wilson, Cameron, PharmD, Health Scientist, Food & Drug Administration - nothing to disclose
- Burke, Kara, PharmD, Team Leader/Pharmacist, FDA/CDER/OCOMM/DDI - nothing to disclose
- Cao, Christian, MPAS, PA-C, Cross-Discipline Safety Advisor, FDA/CDER/OSE/OPE - nothing to disclose
- De Fronzo, Kimberly, RPh, MS, MBA, Consumer Safety Officer, FDA/CDER/OCOMM/DDI - nothing to disclose
- Kapoor, Rama, MD, Senior Physician, FDA - nothing to disclose
- Nguyen-Chu, Thanh, PharmD, Pharmacist, FDA/CDER/OCOMM/DDI - nothing to disclose
- Paraoan, Dianne, MPH, BSN, RN, Associate Director for Regulatory Affairs, FDA/ CDER/ OMP - nothing to disclose
CE Consultation and Accreditation Team
- Littlefield, Jr, Kenneth P., Training Specialist, FDA/CDER/OEP/DLOD - nothing to disclose
- Bryant, Traci, M.A.T., Lead Training Specialist, FDA/CDER/OEP/DLOD - nothing to disclose
- Wood, Sara, Accreditation Program Administrator, CECAT, FDA/CDER/OEP/DLOD - nothing to disclose
All relevant financial relationships have been mitigated.
Registration is complimentary, therefore refunds are not applicable.